Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present INVO BioScience, Inc. (OTC: IVOB).

Full DD Report for IVOB

You must become a subscriber to view this report.


Recent News from (OTC: IVOB)

INVO BioScience reports Q3 results
INVO BioScience ( OTCQB:IVOB ): Q3 GAAP EPS of $0.00. More news on: INVO BioScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 14 2018 16:39
INVO Bioscience Reports Record Third Quarter 2018 Financial Results
MEDFORD, Mass. , Nov. 14, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its Q3 2018 financial results or the quarter ended September 30, 20...
Source: PR Newswire
Date: November, 14 2018 16:05
INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell(TM) System for Use in the Treatment of Infertility
MEDFORD, Mass. , Nov. 13, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical group committed to helping people around the world build families and live better li...
Source: PR Newswire
Date: November, 13 2018 08:00
INVOcell Enables Same-Sex Couple to Both Physically Participate in the Pregnancy and Birth of Their Child
MEDFORD, Mass. , Oct. 31, 2018 /PRNewswire/ --  INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced a successful pregnancy where both partners of a same-sex couple were able to...
Source: PR Newswire
Date: October, 31 2018 09:01
INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo
MEDFORD, Mass. , Oct. 18, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, today announced that two posters were presented at the 74th Scientific Congress & Expo of the Americ...
Source: PR Newswire
Date: October, 18 2018 08:31
INVO BioScience reports Q2 results
INVO BioScience ( OTCQB:IVOB ): Q2 EPS of $0.00 More news on: INVO BioScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 17:12
INVO Bioscience Reports Record Second Quarter 2018 Financial Results
MEDFORD, Mass. , Aug. 14, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its Q2 2018 financial results for the quarter ended June 30, 2018 and r...
Source: PR Newswire
Date: August, 14 2018 16:05
INVO Bioscience Announces Uplisting to OTCQB Market
MEDFORD, Mass. , June 29, 2018 /PRNewswire/ --  INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced today that its stock has commenced trading on the OTCQB Market ("OTCQB") a...
Source: PR Newswire
Date: June, 29 2018 10:00
INVO BioScience reports Q1 results
INVO BioScience ( OTCPK:IVOB ): Q1 EPS of $0.00 More news on: INVO BioScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 15 2018 08:40
INVO Bioscience Reports Record First Quarter 2018 Financial Results
MEDFORD, Mass. , May 15, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced its first quarter 2018 financial results and recent highlights. F...
Source: PR Newswire
Date: May, 15 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-070.450.400.48850.4046,645
2018-12-060.469250.440.48850.4289,251
2018-12-050.5250.490.5250.4568,134
2018-12-040.5250.490.5250.4568,134
2018-12-030.509950.500.550.456183,550

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0729,36746,64562.9585Short
2018-12-0658,41178,37674.5266Short
2018-12-0458,69468,13486.1449Short
2018-12-0351,027183,55027.8001Cover
2018-11-3026,67937,91670.3634Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IVOB.


About INVO BioScience, Inc. (OTC: IVOB)

Logo for INVO BioScience, Inc. (OTC: IVOB)

INVO Bioscience, Inc. offers novel solutions in assisted reproductive technologies ART while expanding geographic and affordable access to the global reproductive health care community. Our primary focus is the manufacture and sale of the INVOcell device and the INVO technology to assist infertile couples in having a baby. We designed our INVOcell device and our INVO procedure to provide an alternative infertility treatment for the patient and the clinician. The INVO procedure is less expensive and simpler to perform than most comparable infertility treatments currently. The simplicity of the INVO procedure relates to the ability to potentially perform the INVO procedure in a physician s practice rather than in a specialized facility at a much lower cost overall than current infertility treatments. lt br / gt lt br / gt We believe that the INVO procedure will make infertility treatment more readily available throughout the world. The INVO procedure is significantly less costly than conventional in vitro fertilization IVF . The INVOcell device and INVO procedure facilitates conception and embryo development inside the woman s body, rather than in a dish in a laboratory, which is an attractive feature for most couples.

 

 

 

Current Management

  • Kathleen T. Karloff / CEO
    • Cofounder of INVO Bioscience, Ms. Karloff has more than years of experience in medical device and pharmaceutical manufacturing, clinical operations, regulatory affairs and quality systems. Katie has been critical to the FDA approval of the INVOcell device as well as the product development and scaleup of the INVOcell. Prior to INVO Bioscience, Katie was the Corporate Vice President of Operations for Psivida Ltd, a start up combination medical device/pharmaceutical technology company whereas she was critical in developing obtaining FDA approval of a novel ocular implant. Katie also served over years at Boston Scientific in various operation functions and years on the senior management teams of other startup organizations. Katie has an undergraduate degree in Microbiology and MBA coursework from Northeastern University.
  • Robert J. Bowdring / Treasurer, Secretary
    • Rob Bowdring joined the INVO Bioscience Board of Directors in after serving as the Company s Chief Financial Officer from until . He is currently Chief Financial Officer at Dynasil Corporation, a publiclytraded company that develops and manufactures optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets. Prior to joining INVO Bioscience in , Mr. Bowdring previously he served as Chief Financial Officer of Cyphermint, Inc. from to , and as Vice President and Corporate Controller for Lifeline Systems from to . Prior to , Mr. Bowdring held positions of increasing responsibility at Remanco, Inc., Warburton s Inc., Cyborg Corporation, and Technogenics, Inc. Mr. Bowdring has a B.A. in Accounting from the University of Massachusetts
  • Kathleen T. Karloff / Chairwoman
    • Cofounder of INVO Bioscience, Ms. Karloff has more than years of experience in medical device and pharmaceutical manufacturing, clinical operations, regulatory affairs and quality systems. Katie has been critical to the FDA approval of the INVOcell device as well as the product development and scaleup of the INVOcell. Prior to INVO Bioscience, Katie was the Corporate Vice President of Operations for Psivida Ltd, a start up combination medical device/pharmaceutical technology company whereas she was critical in developing obtaining FDA approval of a novel ocular implant. Katie also served over years at Boston Scientific in various operation functions and years on the senior management teams of other startup organizations. Katie has an undergraduate degree in Microbiology and MBA coursework from Northeastern University.
  • Robert J. Bowdring /
    • Rob Bowdring joined the INVO Bioscience Board of Directors in after serving as the Company s Chief Financial Officer from until . He is currently Chief Financial Officer at Dynasil Corporation, a publiclytraded company that develops and manufactures optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets. Prior to joining INVO Bioscience in , Mr. Bowdring previously he served as Chief Financial Officer of Cyphermint, Inc. from to , and as Vice President and Corporate Controller for Lifeline Systems from to . Prior to , Mr. Bowdring held positions of increasing responsibility at Remanco, Inc., Warburton s Inc., Cyborg Corporation, and Technogenics, Inc. Mr. Bowdring has a B.A. in Accounting from the University of Massachusetts
  • Michael J. Campbell / Independent Director
    • Mr. Campbell is the Vice President of IVF Americas Business Unit for Cooper Surgical, Inc. CSI , a wholly owned subsidiary of The Cooper Companies NYSE: COO . Mr. Campbell has substantial medical device sales, marketing and business development leadership experience within Global Fortune and Startup Company environments. During his over year career at Cooper Surgical, Mike has been responsible for IVF product portfolio sales globally including the US, Canada, Latin America, Europe, Middle East, Africa, and Asia Pacific regions. In addition to Mr. Campbell s current position as Vice President of IVF Americas Business Unit, he served in various leadership roles including Vice President of International Business Unit from and as Vice President of IVF Business Unit from to . Prior to joining Cooper Surgical, Mike was Vice President of Sales, Marketing and Business Development at Retroactive Bioscience from to and Vice President of Sales and Marketing for Gabriel Medical from to . Mr. Campbell also served in various senior management positions across marketing, sales and product management at Boston Scientific Corporation beginning in through .
  • Kevin J. Doody, MD / Independent Director
    • Dr. Kevin Doody serves as Medical Director for INVO Bioscience and is also a member of the Board of Directors. Dr. Doody is a renowned fertility specialist who is the founder and Medical Director for the Center for Assisted Reproduction CARE Fertility and Effortless IVF located in Bedford Texas. The Center for Assisted Reproduction, established in , has been a pioneer of assisted reproductive technologies in the north Texas region with several firsts including the first ICSI pregnancy and the first to successfully implement a blastocyst culture system. CARE Fertility had the first pregnancy in the region with a pregnancy following embryo biopsy and preimplantation genetic testing for cystic fibrosis. CARE Fertility/ Effortless IVF also was the first to adopt the INVOcell Intravaginal Culture System since the INVOcell first obtained FDA clearance. Dr. Doody is President of the Society for Assisted Reproductive Technology SART , on the Board of Directors of the American Society for Reproductive Medicine ASRM and a member of the RESOLVE Physician Council. As INVO Bioscience s Medical Director, Dr. Doody provides medical and clinical guidance, INVO education and training, and oversight of risk management and postmarket surveillance activities as well as support current and new product development.
  • Steven Shum / Independent Director
    • Mr. Shum has served as Chief Financial Officer of Eastside Distilling NASDAQ: ESDI since October . Prior to joining Eastside, Mr. Shum served as an Officer and Director of XZERES Corp, a publiclytraded global renewable energy company, from October until April in various officer roles, including Chief Operating Officer from September until April , Chief Financial Officer, Principal Accounting Officer and Secretary from April until September under former name, Cascade Wind Corp and Chief Executive Officer and President from October to August . Mr. Shum also serves as the managing principal of Core Fund Management, LP and the Fund Manager of Core Fund, LP. He was a founder of Revere Data LLC now part of Factset Research Systems, Inc. and served as its Executive Vice President for four years, heading up the product development efforts and contributing to operations, business development, and sales. He spent six years as an investment research analyst and portfolio manager of D.N.B. Capital Management, Inc. His previous employers include Red Chip Review and Laughlin Group of Companies. He earned a B.S. in Finance and a B.S. in General Management from Portland State University in .

Current Share Structure

  • Market Cap: $42,362,699 - 03/09/2018
  • Authorized: 200,000,000 - 12/17/2008
  • Issue and Outstanding: 141,681,268 - 11/10/2017
  • Float: 47,600,000 - 06/22/2017

 


Recent Filings from (OTC: IVOB)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: January, 31 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: January, 24 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: January, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 11 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: September, 05 2017

 

 


Daily Technical Chart for (OTC: IVOB)

Daily Technical Chart for (OTC: IVOB)


Stay tuned for daily updates and more on (OTC: IVOB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IVOB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IVOB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IVOB and does not buy, sell, or trade any shares of IVOB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/